title: Pulmonary function in human immunodeficiency virus infection. A prospective 18-month study of serial lung function in 474 patients.
abstract: To investigate the development of a reduced DLCO in patients with HIV-related disease, we studied 474 HIV-seropositive patients and performed serial lung function measurements over 18 months. The mean values of DLCO at presentation were lower in patients with more advanced HIV disease compared with asymptomatic HIV-seropositive patients (DLCO 88% of predicted). When compared with the DLCO in asymptomatic HIV-seropositive patients, the DLCO had reduced values in patients with persistent generalized lymphadenopathy (PGL) (82% of predicted, p less than 0.05), acquired deficiency syndrome-related complex (ARC) (73% predicted, p less than 0.001), nonpulmonary Kaposi's sarcoma (KS) (72% of predicted, p less than 0.001), nonpulmonary complications of AIDS excluding KS (73% of predicted, p less than 0.001), pulmonary KS (63% of predicted, p less than 0.001), pulmonary mycobacterial infection (68% of predicted, p less than 0.05), pyogenic infection (70%, p less than 0.05), acute Pneumocystis carinii pneumonia (PCP; 49%, p less than 0.001), and following recovery from PCP (71%, p less than 0.001). Serial lung function measurements over 18 months revealed no change in DLCO within any patient group, and in particular there was no tendency for a gradual decline. Clinical deterioration due to the development of PCP was associated with a reduction in DLCO. Conversely, in patients recovering from PCP, there was a partial improvement in DLCO over 3 months. Zidovudine (AZT) use did not affect DLCO within any diagnostic group or the recovery in DLCO following PCP. However, cigarette smoking was associated with further reductions in DLCO in all patient groups and with an impaired recovery of DLCO following acute PCP.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Respiratory Medicine, St. Mary's Hospital, London, United Kingdom.
authors.forename: D M
authors.initials: DM
authors.lastname: Mitchell
authors.forename: J
authors.initials: J
authors.lastname: Fleming
authors.forename: A J
authors.initials: AJ
authors.lastname: Pinching
authors.forename: J R
authors.initials: JR
authors.lastname: Harris
authors.forename: F M
authors.initials: FM
authors.lastname: Moss
authors.forename: D
authors.initials: D
authors.lastname: Veale
authors.forename: R J
authors.initials: RJ
authors.lastname: Shaw
mesh_terms: D000386:AIDS-Related Complex / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D000704:Analysis of Variance; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D006679:HIV Seropositivity / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D015497:HIV-1; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D009894:Opportunistic Infections / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology; D011446:Prospective Studies; D011653:Pulmonary Diffusing Capacity / Q000187:drug effects; D012907:Smoking / Q000503:physiopathology; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D015215:Zidovudine